Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 2
1988 1
1989 13
1990 27
1991 43
1992 66
1993 65
1994 72
1995 51
1996 71
1997 65
1998 67
1999 72
2000 108
2001 162
2002 167
2003 188
2004 223
2005 254
2006 336
2007 358
2008 452
2009 502
2010 617
2011 682
2012 783
2013 905
2014 865
2015 900
2016 925
2017 882
2018 912
2019 991
2020 1071
2021 1014
2022 906
2023 875
2024 777

Text availability

Article attribute

Article type

Publication date

Search Results

14,487 results

Results by year

Filters applied: . Clear all
Page 1
HER-2 Positive Breast Cancer - a Mini-Review.
Asif HM, Sultana S, Ahmed S, Akhtar N, Tariq M. Asif HM, et al. Asian Pac J Cancer Prev. 2016;17(4):1609-15. doi: 10.7314/apjcp.2016.17.4.1609. Asian Pac J Cancer Prev. 2016. PMID: 27221828 Free article. Review.
The human epidermal growth factor receptor 2 (HER-2) is a receptor tyrosine-protein kinase erbB-2 normally involved in the proliferation and division of breast cells. ...HER2 targeted therapies, has significantly improved the thera …
The human epidermal growth factor receptor 2 (HER-2) is a receptor tyrosine-protein kinase erbB-2 …
Breast Cancer Treatment: A Review.
Waks AG, Winer EP. Waks AG, et al. JAMA. 2019 Jan 22;321(3):288-300. doi: 10.1001/jama.2018.19323. JAMA. 2019. PMID: 30667505 Review.
IMPORTANCE: Breast cancer will be diagnosed in 12% of women in the United States over the course of their lifetimes and more than 250 000 new cases of breast cancer were diagnosed in the United States in 2017. ...Triple-negative breast cancer …
IMPORTANCE: Breast cancer will be diagnosed in 12% of women in the United States over the course of their lifetimes and more t …
Multigene expression signatures in early hormone receptor positive HER 2 negative breast cancer.
Ovcaricek T, Takac I, Matos E. Ovcaricek T, et al. Radiol Oncol. 2019 Sep 24;53(3):285-292. doi: 10.2478/raon-2019-0038. Radiol Oncol. 2019. PMID: 31553709 Free PMC article. Review.
Background The standard treatment of hormone receptor positive, HER2 negative early breast cancer (BC) is surgery followed by adjuvant systemic therapy either with endocrine therapy alone or with the addition of chemotherapy followed by endocrine thera …
Background The standard treatment of hormone receptor positive, HER2 negative early breast cancer (BC) is surger …
Prevalence of HER-2-positive invasive breast cancer: a systematic review from Iran.
Keyhani E, Muhammadnejad A, Karimlou M. Keyhani E, et al. Asian Pac J Cancer Prev. 2012;13(11):5477-82. doi: 10.7314/apjcp.2012.13.11.5477. Asian Pac J Cancer Prev. 2012. PMID: 23317203 Free article. Review.
BACKGROUND: The HER-2/neu gene is altered in 15-20% of breast cancer patients. Immunohistochemistry (IHC) is considered to be the most cost-effective method for HER-2 detection in many countries. Approximately 8,000 new cases of breast …
BACKGROUND: The HER-2/neu gene is altered in 15-20% of breast cancer patients. Immunohistochemistry (IHC) is con …
HER-2 positive breast cancer: what else beyond trastuzumab-based therapy?
Widakowich C, Dinh P, de Azambuja E, Awada A, Piccart-Gebhart M. Widakowich C, et al. Anticancer Agents Med Chem. 2008 Jun;8(5):488-96. doi: 10.2174/187152008784533062. Anticancer Agents Med Chem. 2008. PMID: 18537532 Review.
HER-2 is a tyrosine kinase receptor which is overexpressed in 20-25% of breast cancer patients and is associated with poor prognosis. Trastuzumab, a humanized monoclonal antibody directed against the HER-2 receptor, used alo …
HER-2 is a tyrosine kinase receptor which is overexpressed in 20-25% of breast cancer patients and is ass …
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P, Baselga J. Gianni L, et al. Lancet. 2010 Jan 30;375(9712):377-84. doi: 10.1016/S0140-6736(09)61964-4. Lancet. 2010. PMID: 20113825 Clinical Trial.
BACKGROUND: The monoclonal antibody trastuzumab has survival benefit when given with chemotherapy to patients with early, operable, and metastatic breast cancer that has HER2 (also known as ERBB2) overexpression or amplification. We aimed to assess event-free surviv …
BACKGROUND: The monoclonal antibody trastuzumab has survival benefit when given with chemotherapy to patients with early, operable, and meta …
Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.
Gonzalez-Angulo AM, Hortobágyi GN, Esteva FJ. Gonzalez-Angulo AM, et al. Oncologist. 2006 Sep;11(8):857-67. doi: 10.1634/theoncologist.11-8-857. Oncologist. 2006. PMID: 16951389 Free article. Review.
Breast cancer is the most common cancer in women in the U.S. and western Europe. Amplification of the her-2/neu gene occurs in approximately 25% of invasive ductal carcinomas of the breast. In experimental models, transfection of the h …
Breast cancer is the most common cancer in women in the U.S. and western Europe. Amplification of the her-2 …
Progress and new standards of care in the management of HER-2 positive breast cancer.
Demonty G, Bernard-Marty C, Puglisi F, Mancini I, Piccart M. Demonty G, et al. Eur J Cancer. 2007 Feb;43(3):497-509. doi: 10.1016/j.ejca.2006.10.020. Epub 2007 Jan 12. Eur J Cancer. 2007. PMID: 17223541 Review.
The aim of this review article is to examine the available evidence regarding diagnosis and treatment of HER-2 positive breast cancer. This group of breast tumours (up to 30% of the total number of breast cancers) is known for havi …
The aim of this review article is to examine the available evidence regarding diagnosis and treatment of HER-2 positive …
Screening a Prognosis-Related Target Gene in Patients with HER-2-Positive Breast Cancer by Bioinformatics Analysis.
Wang S, Deng J, Gao X, Lv H, Quan Y. Wang S, et al. Med Princ Pract. 2021;30(4):376-384. doi: 10.1159/000516322. Epub 2021 Apr 6. Med Princ Pract. 2021. PMID: 33823519 Free PMC article.
OBJECTIVE: The objective of the present study was to determine a target gene and explore the molecular mechanisms involved in the pathogenesis of HER-2-positive breast cancer. METHODS: Three RNA expression profiles obtained from the Gene Express …
OBJECTIVE: The objective of the present study was to determine a target gene and explore the molecular mechanisms involved in the pathogenes …
Assessment of HER-2 status in invasive breast cancer in Brazil.
Arias VEA, Gobbi H, Ioshii SO, Scapulatempo C, Paz ARD, Silva VDD, Uchôa D, Zettler C, Soares FA. Arias VEA, et al. Rev Assoc Med Bras (1992). 2017 Jul;63(7):566-574. doi: 10.1590/1806-9282.63.07.566. Rev Assoc Med Bras (1992). 2017. PMID: 28977081 Free article.
OBJECTIVE: To characterize the frequency of HER-2-positive breast cancer in Brazil. METHOD: In this prospective observational study, we first ascertained the HER-2 status of invasive breast cancer specimens by automat …
OBJECTIVE: To characterize the frequency of HER-2-positive breast cancer in Brazil. METHOD: In this prosp …
14,487 results
You have reached the last available page of results. Please see the User Guide for more information.

Searches related to "her-2 positive breast cancer"